未知股票 CARV 深 沪
等待开盘
--
0.000
NaN.00%
华盛通- 最 高--
- 今 开--
- 成交量 --
- 最 低 --
- 昨 收 --
- 总市值 0
- 52周最高 --
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 --
- 委 比 0.00%
- 总股本 528.71万
- 历史最高 --
- 量 比 0
- 振 幅 NaN.00%
- 历史最低 --
- 每 手 1
- 风险率 0.54%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Carver Bancorp appoints Lisa Robinson Smith as CFO
Carver Bancorp (CARV) on Monday announced the appointment of Lisa Robinson Smith as Chief Financial Officer. Robinson Smith, who has served as the company's Deputy Chief Financial Officer since June ...
03-23 20:36
BRIEF-Carver Bancorp, Inc. Appoints Lisa Robinson Smith As Chief Financial Officer
BRIEF-Carver Bancorp, Inc. Appoints Lisa Robinson Smith As Chief Financial Officer Carver Bancorp Inc CARV.PK : CARVER BANCORP, INC. APPOINTS LISA ROBINSON SMITH AS CHIEF FINANCIAL OFFICER Source text: ID:nPn9RKPvSa Further company coverage: CARV.PK
03-23 20:34
传奇生物公布2025年第四季度和全年业绩
(医药健闻2026年3月11日讯）传奇生物科技公司公布了截至2025年12月31日第四季度及全年财务业绩，以及公司主要重点。截至2025年12月31日止三个月合...
03-11 15:37
Legend Biotech Q4 net loss widens to USD 30.9 million as collaboration revenue rises 65% to USD 277.6 million
Legend Biotech Q4 net loss widens to USD 30.9 million as collaboration revenue rises 65% to USD 277.6 million Legend Biotech reported Q4 total revenue of USD 306.3 million, up 64%, driven by higher collaboration revenue from CARVYKTI sales under the Janssen agreement. Q4 collaboration revenue rose 6
03-10 19:09
BRIEF-Gotham City Research Releases Report On Carvana
BRIEF-Gotham City Research Releases Report On Carvana Jan 28 (Reuters) - GOTHAM CITY RESEARCH RELEASES REPORT ON CARVANA GOTHAM CITY RESEARCH - HOLDS SHORT POSITIONS IN CARVANA STOCK Source text: [ https://tinyurl.com/yp839m2a ] Further company coverage: CVNA.N (( Reuters.Briefs@thomsonreuters.com ;
01-29 00:33
Legend Biotech To Present Six Poster Presentations Featuring Data On CARVYKTI At Tandem Meetings Of ASTCT And CIBMTR
Six poster presentations highlight CARVYKTI® efficacy, safety, and real-world outcomes across CARTITUDE trials and analyses, reflecting a maturing and expanding body of evidenceSOMERSET, N.J., Jan. 21, 2026 (GLOBE
01-21 21:10
Legend Reports US$555 Million CARVYKTI Sales for Q4 2025
Legend Reports US$555 Million CARVYKTI Sales for Q4 2025 GenScript Biotech Corporation announced that its associate, Legend Biotech Corporation, reported preliminary net trade sales of approximately US$555 million for CARVYKTI® for the quarter ended 31 December 2025. This update follows previous ann
01-21 20:58
Legend Biotech Reports Preliminary $555 Million CARVYKTI Sales for Q4 2025
Legend Biotech Reports Preliminary $555 Million CARVYKTI Sales for Q4 2025 Legend Biotech Corporation announced preliminary business results for the quarter ended December 31, 2025. According to information provided by Janssen, CARVYKTI® generated approximately $555 million in net trade sales during
01-21 20:30
Johnson & Johnson Q4 sales beat estimates
Johnson & Johnson Q4 sales beat estimates Overview Healthcare co's Q4 sales rose 9.1%, beating analyst expectations Adjusted EPS for Q4 beat analyst expectations Company highlights "significant" innovation in medical portfolio Outlook Johnson & Johnson forecasts 2026 reported sales of $100.5 bln at
01-21 19:28
ROI-US squeeze on Venezuela oil won’t create global crunch: Bousso
The opinions expressed here are those of the author, a columnist for Reuters. By Ron Bousso LONDON, Dec 15 (Reuters) - The United States' tightening grip on Venezuela’s oil exports could strangle the ...
2025-12-15 15:00
